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Abstract
Objectives:  Clinical  use  of  microarray-based  techniques  for  the  analysis  of  many  developmen-
tal disorders  has  emerged  during  the  last  decade.  Thus,  chromosomal  microarray  has  been
positioned  as  a  ﬁrst-tier  test.  This  study  reports  the  ﬁrst  experience  in  a  Chilean  cohort.
Methods: Chilean  patients  with  developmental  disabilities  and  congenital  anomalies  were  stud-
ied with  a  high-density  microarray  (CytoScanTM HD  Array,  Affymetrix,  Inc.,  Santa  Clara,  CA,
USA). Patients  had  previous  cytogenetic  studies  with  either  a  normal  result  or  a  poorly  charac-
terized anomaly.
Results:  This  study  tested  40  patients  selected  by  two  or  more  criteria,  including:  major  con-
genital anomalies,  facial  dysmorphism,  developmental  delay,  and  intellectual  disability.  Copy
number variants  (CNVs)  were  found  in  72.5%  of  patients,  while  a  pathogenic  CNV  was  found  in
25% of  patients  and  a  CNV  of  uncertain  clinical  signiﬁcance  was  found  in  2.5%  of  patients.
Conclusion:  Chromosomal  microarray  analysis  is  a  useful  and  powerful  tool  for  diagnosis  of
developmental  diseases,  by  allowing  accurate  diagnosis,  improving  the  diagnosis  rate,  and
discovering  new  etiologies.  The  higher  cost  is  a  limitation  for  widespread  use  in  this  setting.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved. Please cite this article as: Lay-Son G, Espinoza K, Vial C, Rivera JC, Guzmán ML, Repetto GM. Chromosomal microarrays testing in children
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Análise  cromossômica  por  microarray  em  crianc¸as com  deﬁciências  de
desenvolvimento  e  anomalias  congênitas
Resumo
Objetivo:  O  uso  clínico  de  técnicas  baseadas  em  microarrays  para  a  análise  de  transtornos  de
desenvolvimento  tem  surgido  durante  a  última  década.  Assim,  o  microarray  cromossômico  tem
sido posicionado  como  um  teste  de  primeiro  nível  clínico.  Relatamos  a  primeira  experiência  em
uma coorte  chilena.
Métodos:  Pacientes  chilenos  com  atraso  de  desenvolvimento  e  anomalias  congênitas  foram
estudados  com  um  microarray  de  alta  densidade  (CytoScanTM HD  Array,  Affymetrix,  Inc.,  Santa
Clara, CA,  EUA).  Pacientes  tiveram  estudos  citogenéticos  anteriores,  ou  um  resultado  normal
ou de  uma  anomalia  não  bem  caracterizada.
Resultados:  Foram  analisados  40  pacientes  selecionados  por  dois  ou  mais  critérios,  incluindo:
anomalias congênitas  maiores,  dismorﬁsmo  facial,  atraso  de  desenvolvimento  e  deﬁciência  int-
electual.  Uma  variante  do  número  de  cópia  (CNV)  foi  encontrada  em  72,5%  dos  pacientes,
enquanto que  uma  CNV  patogênica  foi  encontrada  em  25%  dos  pacientes  e  uma  CNV  de  signiﬁ-
cado clínico  incerto  foi  encontrada  em  2,5%  dos  pacientes.
Conclusões:  A  análise  cromossômica  microarray  é  uma  ferramenta  útil  e  poderosa  em
transtornos  de  desenvolvimento,  permitindo  um  diagnóstico  preciso,  melhorando  a  taxa  de
diagnóstico,  e  descobrindo  novas  etiologias.  O  custo  mais  elevado  é  uma  limitac¸ão  para  um  uso
difundido  em  nossa  realidade.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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cause  for  the  disorder.ntroduction
ajor  congenital  anomalies  affect  two  to  three  of  every  100
ive  newborns,  and  are  a  leading  cause  of  infant  mortality
nd  disability.1,2 Although  most  are  isolated  and  multifacto-
ial  in  origin,  patients  with  multiple  abnormalities  require
n  assessment  to  identify  an  underlying  genetic  cause.
In  recent  years,  the  etiological  study  of  developmen-
al  disorders  has  been  enriched  with  the  clinical  use
f  microarray-based  techniques.  In  developed  countries,
olecular  karyotyping  or  chromosomal  microarray  (CMA)
s  considered  the  ﬁrst-line  technique  for  the  analysis  of
atients  with  multiple  congenital  anomalies,  nonsyndromic
evelopmental  delay/intellectual  disability,  and  autism
pectrum  disorders.3--7
In  contrast,  in  developing  nations  such  as  Latin  Amer-
can  countries,  detection  of  chromosomal  anomalies  is
till  performed  mainly  by  conventional  cytogenetic  tech-
iques.  GTG  (G-bands  by  trypsin  using  Giemsa)  banding
aryotyping  in  lymphocytes  has  been  mainly  used  to  iden-
ify  chromosomal  abnormalities  with  a  resolution  equal
r  greater  than  5-10  megabases  (5-10  Mb).8--11 Fluores-
ent  in  situ  hybridization  (FISH)  is  available  for  a  limited
umber  of  diseases  caused  by  chromosomal  microdele-
ions/microduplications  and  has  a  resolution  of  2-5  Mb
n  metaphase  and  between  50-150  Kb  in  interphase
uclei.8,9,11--13 Other  molecular  techniques  have  been  devel-
ped  to  look  for  small  microdeletions/microduplications,
uch  as  multiplex  ligation-dependent  probe  ampliﬁcation
MLPA).14 In  contrast  to  these  conventional  techniques,  CMA
as  a  higher  resolution,  which  reaches  up  to  50  Kb,  a  ten
imes  higher  resolution  than  conventional  karyotyping.13,15
t  seeks  genetic  imbalances  (gains  or  losses  of  chromosomal
h
segments)  across  the  genome  and  has  allowed  the  identiﬁ-
ation  of  new  syndromes  that  are  not  readily  detected  by
he  methods  described  above.16--18 The  discovery  of  normal
ariation  as  copy  number  variations  (CNVs)  poses  a  challenge
or  the  clinical  interpretation.15
Whilst  diagnostic  studies  for  individuals  with  congenital
nomalies  or  intellectual  disability  based  on  conventional
ytogenetics  have  a  diagnostic  yield  close  to  3%,  CMA  has  a
ield  of  around  15%  to  20%,  over  ﬁve  timesgreater  than  G-
anded  karyotype,6 justifying  its  use  as  a  ﬁrst  line  diagnostic
est  for  patients  with  an  unknown  clinical  diagnosis.  It  is
stimated  that  CMA  alone  is  capable  of  detecting  over  99%
f  all  karyotype  abnormalities.5
This  report  presents  the  authors’  pioneering  experience
n  the  use  of  CMA  in  a  cohort  of  Chilean  patients  with  mul-
iple  congenital  anomalies  without  etiological  diagnosis.
ethods
atients
orty  patients  were  selected  from  the  Genetic  Clinics  at  Hos-
ital  Padre  Hurtado  (Santiago,  Chile),  between  May  of  2012
nd  November  of  2012.
This  study  included  patients  who  had  at  least  two  of
he  following  clinical  features:  major  congenital  anomalies
MCAs),  facial  dysmorphism  (FD),  developmental  delay  (DD),
r  intellectual  disability  (ID).  All  patients  lacked  a  deﬁniteOf  all  patients,  36  had  a  normal  karyotype,  two  patients
ad  an  uncharacterized  small  additional  marker  chromo-
ome  (sSMC),  one  had  a  derivative  chromosome,  one  had  an
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inherited  Robertsonian  translocation,  and  one  patient  had
monosomy  X,  but  with  unusual  additional  features.
The  local  ethics  committee  approved  this  study,  and  writ-
ten  informed  consent  was  obtained  from  all  patients  and/or
parents/guardians.
Sample  Processing
Genomic  DNA  was  puriﬁed  from  peripheral  blood  mono-
nuclear  cells  with  AxyPrep  Blood  Genomic  DNA  Miniprep  Kit
(Axygen  Biosciences,  Union  City,  CA,  USA)  following  manu-
facturer’s  instructions.  Genomic  DNA  of  each  patient  was
hybridized  with  the  CytoScanTM HD  Array  (Affymetrix,  Inc.,
Santa  Clara,  CA,  USA)  according  to  manufacturer’s  instruc-
tions.  This  is  a  custom  high-density  comparative  genomic
hybridization  array  with  almost  2.7  million  of  genetic
markers,  includes  700,000  single  nucleotide  polymorphism
(SNP)  markers  and  over  1.9  oligonucleotide  non-polymorphic
probes  for  CNV  detection.
Data  Analysis
Array  data  were  analyzed  using  the  Affymetrix® Chromo-
some  Analysis  Software  Suite  (ChAS)  v.1.2.2  (Affymetrix,
Inc.,  Santa  Clara,  CA,  USA)  based  on  the  reference  genome
sequence  of  the  UCSC  Genome  Browser  hg19,  Feb.  2009
(GRCh37/hg19).  The  authors  analyzed  CNVs  over  400  Kb
as  recommended.6 With  this  higher-resolution  platform,
it  was  possible  to  evaluate  smaller  CNVs,  but  no  patient
had  clinically  relevant  abnormalities  between  100  and  400
Kb,  so  this  limit  was  kept  for  purposes  of  this  report.
CNVs  over  400  Kb  were  categorized  by  clinical  signiﬁ-
cance  as  CNV  of  clear  clinical  relevance  (group  1),  CNV  of
unclear  relevance  or  uncertain  signiﬁcance  (group  2),  or
benign  or  polymorphic  CNV  (group  3),  using  the  publicly
available  databases  ISCA  (International  Standard  Cytoge-
nomic  Array),19 DGV  (Database  of  Genomic  Variants),20,21
OMIM  (Online  Mendelian  Inheritance  in  Man),22 DECI-
PHER(Database  of  Chromosomal  Imbalance  and  Phenotype  in
Humans  Using  Ensembl  Resources)23,24 and  ECARUCA  (Euro-
pean  Cytogeneticists  Association  Register  of  Unbalanced
Chromosome  Aberrations).25
Results
Of  the  40  patients  analyzed,  16  (41%)  were  female.  Ages
ranged  from  1  month  to  25  years,  with  a  median  age  of
4.2  years.  As  selected,  the  vast  majority  of  the  patients
have  multiple  anomalies,  including  structural  and  functional
developmental  disorders.  Clinical  details  are  summarized  in
Table  1.
CNV  characterization  (Fig.  1)
Fifty-ﬁve  CNVs  over  400  Kb  were  observed  in  29  of  40
patients  (72.5%),  ranging  between  0  and  4  CNVs  per  patient.
Of  the  total,  11  were  losses  and  44  were  gains  (Fig.  1A).  The
size  of  chromosomal  imbalances  ranged  from  420.9  Kb  to
25.2  Mb.  The  latter  corresponded  to  one  patient  with  an
sSMC  detected  by  karyotype.
a
h
d191
These  55  CNVs  were  classiﬁed  into  three  groups  based  on
heir  clinical  interpretation.
According  to  the  classiﬁcation  adopted  (Fig.  1B),  21.8%
elonged  to  group  1  (clear  clinical  relevance  related  to  the
henotype),  1.8%  to  group  2  (unclear  relevance),  and  76.4%
o  group  3  (benign  or  polymorphic).  Losses  were  predom-
nant  in  group  1,  while  gains  were  predominant  in  group
.
iagnostic  yield
n  Group  1,  two  patients  had  two  terminal  chromosome
mbalances,  each  probably  derived  from  unbalanced  cryptic
ranslocations.  Seven  patients  had  a microdeletion  and  one
atient  had  a  mosaic  partial  trisomy  20  (one  of  the  patients
ad  an  sSMC).  More  details  are  summarized  in  Table  1.
In  Group  2,  only  one  patient  had  a  variant  of  uncertain
igniﬁcance  (VOUS).26 This  patient  had  a  2  Mb  triplication
t  9p23  [arr  9p23(9,323,653-11,359,708)x3],  but  with  the
nformation  available  in  the  databases  and  in  biomedical
iterature,  a  deﬁnitive  pathogenic  effect  could  not  be  ruled
ut  or  assigned.
The  authors  failed  to  ﬁnd  true  genetic  imbalances  in
he  second  patient  with  an  sSMC  and  the  patient  with  a
erivative  chromosome  16.  In  the  patient  with  the  Robert-
onian  translocation,  no  genomic  imbalance  that  explained
he  phenotype  was  found.  Finally,  in  the  patient  with  mono-
omy  X,  the  deletion  of  one  X  was  conﬁrmed,  but  additional
enomic  imbalances  were  not  found  (Table  1).
linical  interpretation
his  study  found  a  pathogenic  CNV  that  was  not  previously
bserved  by  (n  =  9)  or  not  well  characterized  (n  =  1)  by  con-
entional  karyotype  in  ten  of  40  patients  of  group  1  (25.0%).
n  addition,  a  known  cytogenetic  anomaly  in  one  patient  was
orroborated  (monosomy  X).
If  only  the  patients  with  normal  karyotype  are  considered
35  patients),  the  diagnosis  rate  increased  to  28.5%.
Additionally,  this  study  found  a  CNV  of  uncertain  clinical
igniﬁcance  or  VOUS  (group  2)  in  one  additional  patient.  This
atient  is  waiting  for  additional  testing  and  follow  up  to
eﬁne  the  clinical  relevance  of  this  ﬁnding.  It  is  planned  to
tudy  both  parents  with  FISH  and/or  MLPA.
iscussion
his  is  the  ﬁrst  report  of  the  CMA  testing  in  a  cohort  of
hilean  patients  with  developmental  disabilities,  consid-
ring  that  there  are  few  studies  of  the  clinical  use  of
hromosomal  microarrays  in  Latin  America,  as  experiences
f  individual  cases  are  the  norm.  Within  South  Amer-
ca,  a  similar  experience  was  reported  with  a group  of
atients  from  Brazil.27,28 Those  authors  analyzed  95  syn-
romic  patients  with  normal  karyotypes  and  reported  a
iagnostic  yield  of  17%.28The  present  study  detected  over  25%  pathogenic  alter-
tions  in  this  cohort,  which  is  in  the  upper  range  that
as  been  reported  in  the  literature.  In  patients  with  syn-
romic  and  nonsyndromic  developmental  delay/intellectual
192  Lay-Son  G  et  al.
Table  1  Summary  of  clinical  features  and  genetic  imbalances  found  in  this  cohort.
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1 N/A 46,XX arr(1-22,X)x2 
2 N/A 46,XX arr(1 -22,X)x2 
3 N/A  46,XX arr(1-22,X)x2 
4 N/A 46,XY arr(1-22)x2,(XY)x1 
5 46,XY arr(1 -22)x2,(XY)x1
6 N/A 46,XY arr 9p23(9,323,653 -
11,359,708)x3
Variant of unknown
 significance (VUOS)
7 N/A 46,XY arr(1-22)x2,(XY)x1 No genomic imbalances
8 46,XX; FISH 22q (-) arr 6p25.1-p23(6,389,847-
15,124,349)x1 6p25.1p23 deletion
9 N/A 46,XX arr(1 -22,X)x2
10 46,XY,der(16) arr(1 -22)x2,(XY)x1 Pericentric inversion 16
11 N/A 46,XY arr(1-22)x2,(XY)x1
12 N/A 46,XY arr(1-22)x2,(XY)x1
13 46,XX; FISH 22q (-) arr(1-22,X)x2
14 46,XX arr(1-22,X)x2
15 46,XY; FISH 22q (-) arr(1-22)x2,(XY)x1
16 N/A 46,XY arr(1-22)x2,(XY)x1
17 46,XY arr(1-22)x2,(XY)x1
18 46,XX arr(1-22,X)x2
19 47,XX,+mar/46,XX
arr
20p12.3q11.22(7,180,552-
32,402,789)x2~3
Partial trisomy 20 mosaicism
20 N/A 46,XY arr
2q23.2q24.2(150,216,033- 2q23.2q24.3 deletion
161, 228,203)x1
21 46 ,XY; FISH22q (-) arr (1 -22)x 2,(XY) x1 No  genomic  imbalances
22 46,XY; FISH 22q (-) arr 15 q25 .2(83 ,08 3,418-
84,834 ,123)x1 15q25 .2  deletion
23 46 ,XY; FISH 22q (-) arr (1- 22)x 2,(XY) x1 No  genomic  imbalances
No  genomic  imbalances
No  genomic  imbalances
No  genomic  imbalances
No genomic imbalances
No  genomic  imbalances
No  genomic  imbalances
No  genomic  imbalances
No  genomic  imbalances
No  genomic  imbalances
No  genomic  imbalances
No genomic imbalances
No  genomic  imbalances
No genomic imbalances
No genomic imbalances
24 N/A 46 ,XY arr (1- 22)x 2,(XY) x1 No  genomic  imbalances
25 46 ,XX ; FI SH 17 p (-) arr (1- 22,X)x 2 No  genomic  imbalances
26 46 ,XX arr (1- 22,X)x 2 No  genomic  imbalances
27 N/A 46,XY arr (1- 22)x 2,(XY) x1 No  genomic  imbalances
28 N/A
46,XY; FISH 22q (-);
Chromosome
breaka ge analysis (-)
arr (1- 22)x 2,(XY) x1 No  genomic  imbalances
29 46,XX arr (1- 22,X)x 2 No  genomic  imbalances
30
45,XY,der
(14;15)( q10;q10) arr (1 -22)x 2,(XY) x1
Rober tso nian tr anslocation,
no  genomic  imbalances
31 46 ,XX
arr
22q12 .1q12.3(28,966,333-
34,541 ,402)x1
22q12 .1q12.3 de let ion
32 N/A 47,XX ,+mar (ma t);
FISH15 q (-) arr (1- 22,X)x 2
SMC  bisatellited  (NOR
staining),  heteroc hroma tin
mater nally de rived (hea lthy
mother)
33 N/A 46 ,XX ; FISH 22 q (-) arr (1- 22,X)x 2 No  genomic  imbalances
34
46,XY; FISH 7q (-),
22q( -) subtelome res
(-)
arr 6p25 .3 -p25.2(156 ,974-
2,40 0,02 3)x1 6p25.3p25 .2 deletion
35 N/A 46,XY
arr 6p25 .3p25 .2(294 ,910-
3,40 3,87 5)x3,12p13.33(17 3,
786 -3,283 ,049) x1
12p13.33 deletion;
6p25.3p25 .2 tripl ication
36 46 ,XY
arr
14q32 .12 q32 .33(94,17 4,317-
107,285,437)x3,22q13.31q13
.33(47,852,611-
51,197 ,838)x1
22q13  deletion;
14q32 .12 q32 .33 tripl icatio n
37 N/A 46 ,XX ; FI SH 22 q (-)
arr 4q34 .1-
q35 .2(17 4,40 9,811-
190, 957,473)x1
4q34.1q35 .2 deletion
38 N/A 45,X arr Xp22 .33 q28(16 8,546-
155, 233,731)x1
Monosomy  X,  without  other
imbalances
39 46 ,XY arr (1 -22)x 2,(XY) x1 No  genomic  imbalances
40 46 ,XY
arr 19 p13 .3(3,78 8,725-
5,34 6,51 1)x1 19p13 .3  deletion
CMA, chromosomal microarray; FISH, ﬂuorescent in situ hybridization; N/A, not applicable by age; NOR, nucleolar organizer
region; sSMC, supernumerary small marker chromosome.
Chromosomal  microarrays  in  children  
Group 1 Group 2 Group 3
29 patients
40 patients
12 CNVs
9L/3G
1 CNVs
0L/1G
42 CNVs
2L/40G
55 CNVs
11L/44G
0 CNVs
A
B
10 patients 1 patient
11 patients
25 patients
Figure  1  Characterization  of  CNVs  larger  than  400  Kb  in
Chilean  cohort.
A, among  40  patients,  CNVs  were  not  found  in  11  individuals.  In
the remaining  29  patients,  55  CNVs  were  found  (11  losses  and  44
gains).  B,  each  patient  may  have  CNV  of  more  than  one  group  at
a time.  CNVs  were  categorized  by  clinical  signiﬁcance  as  CNV  of
clear  clinical  relevance  (group  1),  CNV  of  uncertain  signiﬁcance
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r(group  2),  or  benign  or  polymorphic  CNV  (group  3).
CNVs, copy  number  variants;  G,  gains;  L,  losses.
disability  with  normal  karyotype/FISH,  meta-analysis  shows
a  diagnostic  yield  of  7.8%-13.8%,  ranging  from  5%  to  50%.5,29
This  is  largely  explained  by  heterogeneity  in  the  design
of  studies,  especially  in  patient  selection,  previous  testing
realized,  and  array  platforms  used.  In  the  present  case,  the
high  rate  of  diagnosis  can  be  explained  by  the  fact  that  the
studied  cohort  was  relatively  small,  had  the  bias  of  very
selected  patients,  many  of  whom  have  remained  for  long
time  without  diagnosis,  and  ﬁnally,  used  a  high-density  plat-
form.
Over  time,  different  online  public  databases  have  col-
lected  phenotypic  and  genomic  information  of  thousands
of  anonymous  patients,  which  allow  elucidating  the  vast
majority  of  CNVs  as  benign  or  polymorphic,  without  further
analysis.  In  fact,  the  majority  of  this  study’s  ﬁndings  were
polymorphic  CNVs  (copy  number  polymorphisms,  [CNPs]),
corroborated  in  those  cytogenomic  databases  and  from  the
authors’  own  cohort  data.  Recurrent  CNVs  over  400  Kb  were
observed  in  half  of  these  patients,  mainly  involving  the
following  chromosomal  loci:  10q11.22,  14q32.22,  16p11.2,
17q21.31,  Yq11.223,  and  Yq11.23.  Only  one  case  that  had
a  VOUS  required  further  analysis  to  determine  possible
pathogenicity.  This  patient  was  one  year  and  11  months,
with  DD,  language  delay,  hearing  deﬁcit,  inguinal  hernia,
and  short  stature.  He  had  a  46,XY  karyotype  and  the  array
showed  a  2  Mb  gain  in  chromosome  9p23,  including  par-
tial  triplication  of  one  gene:  PTPRD. The  protein  Ptprd  is
a  receptor-type  protein-tyrosine  phosphatase,  is  expressed
in  certain  regions  of  the  brain,  such  as  the  hippocampus,  and
could  have  a  role  in  learning  and  memory30 and  the  synaptic
organization.31 No  phenotype  has  been  assigned  to  the  full
triplication  of  this  gene.
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Although  CMA  is  a very  robust  and  reliable  technique,
t  has  limitations:  it  is  unable  to  detect  balanced  genomic
bnormalities  such  as  inversions,  reciprocal,  and  Robert-
onian  translocations.  Depending  on  the  platform  used,
ow-level  mosaicism  and  some  polyploidies  cannot  be
etected.  When  CMA  technique  is  used  as  the  ﬁrst  line  of
tudy,  it  has  been  described  that  this  situation  can  occur  in
.78%  of  cases.5 Finally,  CMA  does  not  give  information  on
osition  of  the  rearrangement,  FISH  is  often  used  as  comple-
entary  method  to  identify  possible  rearrangements  with
mplications  for  genetic  counseling.7,32
In  the  present  cohort,  it  was  found  that  three  patients
ith  previously  known  cytogenetic  abnormalities  resulted
n  a  normal  molecular  karyotype.  As  expected,  the  patient
ho  is  carrier  for  a  Robertsonian  translocation  had  a  nor-
al/balanced  aCGH  result.  In  the  case  of  one  of  the  two
atients  with  sSMC,  the  coverage  of  the  array,  the  genomic
equences  involved,  and  the  size  sSMC  may  explain  why
hat  genetic  material  were  undetected  by  this  method.19
hus,  this  small  bisatellited  chromosome  likely  corresponds
o  highly  repetitive  sequences  typical  of  acrocentric  chro-
osomes  not  included  in  the  array  that  was  demonstrated
y  nucleolus  organizer  region  (NOR)  banding.  In  the  patient
ith  a derivative  chromosome  16,  with  an  abnormal  band-
ng  pattern  and  morphology  (more  metacentric  than  usual),
 pericentric  inversion  is  the  most  plausible  explanation.
Thus,  karyotype  remains  more  suitable  to  evaluate
otential  carriers  of  chromosomal  rearrangements,  couples
ith  recurrent  miscarriage,  or  patients  with  a  distinctive
neuploidy  phenotype.  However,  FISH  is  more  suitable  if  a
peciﬁc  microdeletion  syndrome  is  highly  suspected.7
Chromosome  microarrays  are  a  highly  accurate,  robust,
nd  high-throughput  method.  This  study  used  a  combined
ligonucleotide-based  array  plus  SNP  array,  which  has  many
dvantages,  where  the  SNP  array  signiﬁcantly  improves
he  accuracy  and  sensitivity  of  the  CNV  detection  and
osaicism,  also  allowing  the  detection  of  copy-neutral
ariants.33 In  the  case  of  the  chip  used  in  this  report
Cytoscan  HD,  Affymetrix),  the  platform  chemistry  and
ts  algorithms  analyze  the  oligonucleotide  and  SNP  probes
ndependently,  and  thus  each  CNV  can  be  detected  and
onﬁrmed  at  the  same  time,  without  requiring  any  further
onﬁrmation.32,33 In  this  case,  instead  of  a  conﬁrmation  of
he  array  ﬁnding,  FISH  analysis  allows  for  determination  of
he  type  of  rearrangement.32
A  limitation  for  widespread  use  of  molecular  karyotype
s  the  high  cost  of  the  test.  In  Chile,  CMA  is  approximately
our  to  seven  times  more  expensive  than  a  karyotype  and/or
ISH,  and  is  currently  not  covered  by  health  insurance.  How-
ver,  to  reach  an  early  diagnosis  in  selected  patients  with
ultiple  congenital  anomalies  and/or  global  developmen-
al  delay,  it  can  avoid  unnecessary  testing  (the  ‘‘diagnostic
dyssey’’)  and  allow  focusing  on  speciﬁc  issues,  which  in  the
ong  term  can  be  cost-effective.34--38 It  may  be  expected  that
osts  will  decrease  over  time,  enabling  its  more  widespread
se.  Finally,  it  should  be  mentioned  that  there  are  other
latforms  that  have  lower  resolution  but  at  a  relatively
educed  cost.Recognizing  its  limitations,  there  is  growing  evidence  of
he  clinical  impact  of  this  technology.  In  many  patients,
 deﬁnitive  diagnosis  can  impact  not  only  on  information
nd  counseling  for  their  family  environment,39 but  also
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294  
n  active  surveillance  in  search  of  possible  complications,
mong  other  types  of  medical  interventions.37,38 The  present
ata  show  the  usefulness  of  CMA,  allowing  improved  diag-
ostic  capability  with  remarkable  precision  and  optimization
f  the  management  and  supervision  of  health  in  this  group
f  patients  with  special  needs.
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